Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    22406278 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed Comparative Study of Immunogenicity and Safety of a 2-Dose Regimen of ProQuad® Manufactured With rHA
Conditions: Measles;   Mumps;   Rubella;   Varicella
Intervention: Biological: ProQuad® manufactured with recombinant Human Albumine

Indicates status has not been verified in more than two years